Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2016', provides in depth analysis on Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted pipeline therapeutics. 

The report provides comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) 
- The report reviews Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) Overview 7
Therapeutics Development 8
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Products under Development by Stage of Development 8
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Products under Development by Therapy Area 9
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Products under Development by Indication 10
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Products under Development by Companies 14
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Products under Development by Universities/Institutes 18
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Companies Involved in Therapeutics Development 25
4SC AG 25
Chipscreen Biosciences Ltd 26
Curis, Inc. 27
GlaxoSmithKline Plc 28
HitGen LTD 29
IRBM Science Park SpA 30
Merck & Co., Inc. 31
Sigma-Tau S.p.A. 32
Syndax Pharmaceuticals Inc 33
TetraLogic Pharmaceuticals 34
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Drug Profiles 35
4SC-202 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
CUDC-907 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Drug to Inhibit HDAC-3 for Oncology - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
entinostat - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
HG-3001 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
KDAC-0001 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Largazole - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
N-140 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
remetinostat - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
ST-3595 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
tucidinostat - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
vorinostat - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Dormant Projects 67
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Featured News & Press Releases 69
Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 69
Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 69
May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting 69
Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting 70
Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 71
Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 72
Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer 72
Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team 73
Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 73
Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting 74
Dec 03, 2015: Syndax Announces Multiple Data Presentations on Entinostat at Upcoming San Antonio Breast Cancer Symposium 75
Dec 01, 2015: Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin 76
Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting 77
Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata 77
Sep 30, 2015: 4SC receives funding from the Eurostars programme for further research of its anti-cancer agent 4SC-202 with an epigenetic mode of action 78
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Products under Development by Companies, H2 2016 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Assessment by Monotherapy/Combination Products, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 24
Pipeline by 4SC AG, H2 2016 25
Pipeline by Chipscreen Biosciences Ltd, H2 2016 26
Pipeline by Curis, Inc., H2 2016 27
Pipeline by GlaxoSmithKline Plc, H2 2016 28
Pipeline by HitGen LTD, H2 2016 29
Pipeline by IRBM Science Park SpA, H2 2016 30
Pipeline by Merck & Co., Inc., H2 2016 31
Pipeline by Sigma-Tau S.p.A., H2 2016 32
Pipeline by Syndax Pharmaceuticals Inc, H2 2016 33
Pipeline by TetraLogic Pharmaceuticals, H2 2016 34
Dormant Projects, H2 2016 67
Dormant Projects (Contd..1), H2 2016 68